Lyell Immunopharma LYEL Cash Flow Statement (2020-2026)

NASDAQ LYEL
$16.86 +0.11 (+0.66%)
At close: Nov 11, 2026 · 4:00 PM EST
Reported Financials

Lyell Immunopharma Quarterly Cash Flow Statement

Periods 26 quarters
Latest Sep 2026

Lyell Immunopharma reported cash from operations of -$34.57M and free cash flow of -$34.63M for the quarter ended Sep 2026, down 21.0% year over year. This cash flow statement covers 26 quarters of results from Jun 2020 through Sep 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026 Sep2026
Operating Activities
Net Income
-83.71M-68.14M-36.32M-70.25M-8.40M-66.96M-63.89M-50.85M-52.93M-60.67M-45.81M-44.58M-191.94M-52.20M-42.68M-38.85M-140.72M-24.15M-44.76M-45.53M
Depreciation, Depletion & Amortization
Depreciation & Amortization (CF)Dep. & Amort.
4.57M4.19M4.17M4.62M5.04M5.03M5.06M5.10M5.06M5.02M4.90M4.68M5.03M3.44M3.14M2.57M2.40M2.33M2.22M2.05M
Share-based CompensationStock Comp.
21.18M22.03M22.41M19.12M18.36M13.88M14.22M10.52M8.46M9.16M8.28M7.62M8.08M6.02M5.00M5.23M25.57M4.30M4.53M4.51M
Gains from Sales and DivestituresGains Divest
-0.67M-0.08M-0.01M-0.01M-0.43M-0.64M-0.44M-0.02M-0.40M-0.92M-1.29M-2.47M0.25M0.17M-0.12M
Gains from Investment SecuritiesGains Investment
-36.45M-5.00M-10.00M-2.92M12.92M1.54M-0.02M-0.03M0.00M
Asset Writedowns and ImpairmentWritedown
0.01M0.01M5.00M-5.00M13.00M38.30M1.44M
Other non-cash itemsOther Non-Cash
-18.28M-4.09M4.47M1.80M-4.69M-1.42M1.63M-2.18M1.06M1.34M-0.93M0.51M87.30M0.59M0.69M1.46M67.98M0.75M0.81M1.00M
Change in Working Capital
Change in Account PayablesChange Payables
0.10M2.94M-1.77M0.02M-0.53M2.07M0.38M-1.41M0.43M-0.11M-0.52M-0.57M-2.04M-1.65M-0.23M-0.78M0.33M2.38M-1.46M0.14M
Change in Accrued ExpensesChange Accrued Exp.
4.22M-6.39M-0.77M1.32M5.37M-5.86M2.27M4.61M-1.74M-3.61M0.52M3.09M-1.25M-9.79M-3.33M0.57M4.90M-3.57M4.61M6.20M
Change in Other Operating AssetsOther Assets Change
0.18M0.40M-0.41M0.68M1.30M0.41M-1.05M0.66M-3.15M-0.60M0.84M1.62M-3.64M-2.00M-2.80M-0.42M2.39M-0.09M-3.24M-0.26M
Change in Other Operating LiabilitiesOther Liabilities Change
1.71M3.51M-35.86M2.28M-45.42M-0.11M-0.11M-0.11M-0.11M-0.11M-0.11M0.13M-0.31M-0.11M-0.11M-0.35M-2.16M0.01M0.01M0.01M
Other Working Capital ChangesOther WC Changes
1.53M3.11M-35.45M1.60M-46.72M-0.52M0.94M-0.78M3.04M0.48M-0.95M-1.49M3.32M1.89M2.69M0.07M-4.56M0.10M3.25M0.27M
Cash from OperationsCash from Ops.
-33.21M-47.85M-44.33M-37.10M-40.27M-46.21M-39.16M-37.69M-40.64M-42.02M-38.09M-35.04M-47.24M-54.74M-34.46M-28.58M-32.25M-38.51M-33.92M-34.57M
Investing Activities
Capital ExpendituresCapex
10.27M9.73M7.17M2.79M4.58M1.53M0.93M0.20M0.03M0.03M0.33M0.06M0.04M0.25M0.17M0.06M0.30M0.09M0.26M0.07M
Sales of Property, Plant and EquipmentPP&E (Sale)
0.26M0.02M
Change in Property, Plant and EquipmentChange in PP&E
-10.27M-9.73M-7.17M-2.79M-4.58M-1.53M-0.93M-0.20M-0.03M-0.03M-0.33M-0.06M-0.04M-0.25M-0.17M0.20M-0.28M-0.09M-0.26M-0.07M
Purchase of InvestmentsInvestments Purchased
673.47M406.32M
Sale and Maturity of InvestmentsInvestments Sold
70.33M79.81M121.85M106.50M110.90M142.25M187.10M178.15M156.12M130.04M161.80M133.41M123.70M154.12M93.52M74.14M52.91M54.65M69.39M97.24M
Other Investing Activities (as filed)Other investing (as filed)
0.28M0.00M0.28M0.00M0.00M0.00M0.29M0.00M0.00M1.40M1.69M-0.10M0.00M1.59M0.00M
Cash from Investing ActivitiesCash from Investing
-73.86M-26.12M25.02M-57.09M46.65M32.15M152.91M99.67M-100.69M21.99M45.01M1.92M53.51M69.47M12.65M3.35M-31.37M17.38M15.62M53.59M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt RepaymentsLT Debt Repayment
2.89M2.67M2.73M2.74M2.73M2.41M2.81M2.82M2.82M2.66M2.89M2.90M3.02M3.10M3.16M3.17M3.17M3.19M3.25M3.26M
Net Long-Term Debt Issued (Repaid)Net LT Debt
-2.89M-2.67M-2.73M-2.74M-2.73M-2.41M-2.81M-2.82M-2.82M-2.66M-2.89M-2.90M-3.02M-3.10M-3.16M-3.17M-3.17M-3.19M-3.25M-3.26M
Net Debt Issuances and RepaymentsNet Debt Issuance
-2.89M-2.67M-2.73M-2.74M-2.73M-2.41M-2.81M-2.82M-2.82M-2.66M-2.89M-2.90M-3.02M-3.10M-3.16M-3.17M-3.17M-3.19M-3.25M-3.26M
Change in Capital Stock
Common Stock IssuedStock Issued
7.40M2.56M2.46M5.13M0.96M1.25M0.07M0.88M0.10M0.86M0.44M0.18M50.22M0.03M0.52M0.04M
Net Shares Issued and RepurchasedNet Shares Issued
7.40M2.56M2.46M5.13M0.96M1.25M0.07M0.88M0.10M0.86M0.44M0.18M50.22M0.03M0.52M0.04M
Net Equity Issued and RepurchasedNet Equity Issued
7.40M2.56M2.46M5.13M0.96M1.25M0.07M0.88M0.10M0.86M0.44M0.18M50.22M0.03M0.52M0.04M
Other financing activities (as filed)
-0.37M-0.09M-0.07M-0.05M-0.22M-0.12M-0.08M0.00M0.00M0.00M
Cash from Financing ActivitiesCash from Financing
7.40M2.56M2.46M4.76M0.86M-0.07M1.20M-0.14M0.76M0.03M0.86M0.44M0.00M0.18M50.00M0.22M51.72M0.52M0.04M
Additional items
Change in Cash
-99.68M-71.42M-16.86M-89.43M7.24M-14.13M114.95M61.84M-140.57M-20.00M7.78M-33.12M6.70M14.73M-21.63M24.77M-63.39M30.59M-17.78M19.07M
Ending Cash Balance
294.29M222.88M206.02M116.59M123.83M109.71M224.65M286.50M145.93M125.94M133.71M100.59M107.29M122.02M100.39M125.16M61.77M92.36M74.57M93.64M
Free Cash FlowFCF
-43.48M-57.59M-51.50M-39.89M-44.85M-47.75M-40.09M-37.88M-40.66M-42.05M-38.43M-35.10M-47.29M-54.98M-34.63M-28.64M-32.56M-38.60M-34.18M-34.63M
Net Cash FlowNCF
-99.68M-71.42M-16.86M-89.43M7.24M-14.13M114.95M61.84M-140.57M-20.00M7.78M-33.12M6.70M14.73M-21.63M24.77M-63.39M30.59M-17.78M19.07M

Lyell Immunopharma Cash Flow Statement API

Pull Lyell Immunopharma's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=LYEL&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY